Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 1, 2022
Product Development

Sept. 30 Quick Takes: Intercept NASH candidate fails Phase III, NDA resubmission on track

Plus Zealand to advance glepaglutide to NDA and updates from Valneva and YS Pharma
BioCentury | May 4, 2021
Management Tracks

Guardant unveils Eagle as CMO; plus Karyopharm, Arix, Eagle, Gemini, Neoleukin, MEI, Krystal, Relay and more

Cancer diagnostics company Guardant Health Inc. (NASDAQ:GH) hired Craig Eagle as CMO. Eagle, who was most recently was VP of medical affairs oncology at Genentech Inc., is a 19-year veteran of
BioCentury | Sep 27, 2019
Clinical News

Incyte lining up pemigatinib filing on ESMO data

BioCentury | May 17, 2019
Emerging Company Profile

89bio: standing out in the NASH crowd

89bio thinks its FGF21 analog could be superior to other compounds that aim to treat the underlying metabolic causes of NASH
Items per page:
1 - 10 of 13